AbbVie To Switch Track In Alzheimer’s From Tau To Beta-Amyloid

Citing the FDA approval of Biogen’s Aduhelm, AbbVie tells quarterly call it will end development of anti-tau Alzheimer’s candidate and seek to develop a quick-acting beta-amyloid therapy.

Brain decline and dementia or aging as memory loss concept for brain cancer decay or an Alzheimer's disease with old rusting mechanical gears and cog wheels in the shape of a human head with rust.
AbbVie joins the rush to test beta-amyloid hypothesis in Alzheimer's

The major revelation coming out of AbbVie Inc.’s second quarter sales and earnings report, which was largely as expected, was that the firm is abandoning a Phase II tau-targeted Alzheimer’s disease candidate and working to advance a beta-amyloid-targeting agent in clinical development later this year or early in 2022.

Multiple analysts called AbbVie’s change of direction in Alzheimer’s somewhat expected, given the recent US Food and Drug Administration approval...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.